These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10317355)

  • 1. Conditions for the use of methadone; intent to propose revisions to regulations and request for comments.
    Fed Regist; 1983 Sep; 48(178):41049-51. PubMed ID: 10317355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB). Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 Jan; 70(2):291-4. PubMed ID: 15630794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clients of an unauthorized program of methadone treatment.
    Goldberg EL; Nightingale SL
    Public Health Rep; 1975; 90(2):154-8. PubMed ID: 805450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Substitution treatment of drug-dependent patients].
    Sonntag I
    Gesundheitswesen; 1995 Jan; 57(1):36-8. PubMed ID: 7888722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid drugs in maintenance and detoxification treatment of opiate addiction; Substance Abuse and Mental Health Services Administration, HHS. Final rule.
    Fed Regist; 2001 Jan; 66(11):4076-102. PubMed ID: 11503765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The costs of pursuing accreditation for methadone treatment sites: results from a national study.
    Zarkin GA; Dunlap LJ; Homsi G
    Eval Rev; 2006 Apr; 30(2):119-38. PubMed ID: 16492995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of the Methamphetamine Anti-Proliferation Act; thresholds for retailers and for distributors required to submit mail order reports; changes to mail order reporting requirements. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Oct; 68(194):57799-804. PubMed ID: 14535265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiologic aspects of street drug abuse.
    Church EJ
    Radiol Technol; 2001; 73(2):139-64; quiz 169-71. PubMed ID: 11764549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methadone diversion.
    Bourne PG
    Proc Natl Conf Methadone Treat; 1973; 2():839-41. PubMed ID: 4808308
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.
    Peirce JM; Petry NM; Stitzer ML; Blaine J; Kellogg S; Satterfield F; Schwartz M; Krasnansky J; Pencer E; Silva-Vazquez L; Kirby KC; Royer-Malvestuto C; Roll JM; Cohen A; Copersino ML; Kolodner K; Li R
    Arch Gen Psychiatry; 2006 Feb; 63(2):201-8. PubMed ID: 16461864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription Drug Marketing Act Pedigree Requirements; effective date and compliance policy guide; request for comment. Final rule; announcement of effective date; notice of availability; request for comment.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(114):34249-51. PubMed ID: 16795943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guiding principles of international and federal laws pertaining to medical use and diversion of controlled substances.
    Joranson DE
    NIDA Res Monogr; 1993; 131():18-34. PubMed ID: 8413529
    [No Abstract]   [Full Text] [Related]  

  • 14. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are we winning the war against drug addiction?
    Klumpp TG
    Med Times; 1974 Sep; 102(9):39-46. PubMed ID: 4850632
    [No Abstract]   [Full Text] [Related]  

  • 16. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of the diversion of clinic methadone to the street market.
    Berger H
    Proc Natl Conf Methadone Treat; 1973; 2():1264-6. PubMed ID: 4808277
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
    Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
    Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Enforcement Administration--Records and reports of registrants; central recordkeeping permits. Final rule.
    Fed Regist; 1980 Jul; 45(128 Pt 1):44266-7. PubMed ID: 10247077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.